Compare Magnolia Oil & Gas Corporation Class A Common Stock (MGY) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Magnolia Oil & Gas Corporation Class A Common Stock vs Moderna, Inc. — how do they compare? Magnolia Oil & Gas Corporation Class A Common Stock trades at $24.9 (market cap $6.76B), while Moderna, Inc. trades at $223.24 (market cap $86.33B). The key difference: Moderna, Inc. is far larger — about 12.8× Magnolia Oil & Gas Corporation Class A Common Stock's market cap, and Magnolia Oil & Gas Corporation Class A Common Stock pays a 2.63% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Magnolia Oil & Gas Corporation Class A Common Stock for 0 Days and Moderna, Inc. for 59 Days on average.
| MGY | MRNA | |
|---|---|---|
Market Cap | $6.76B | $86.33B |
Volume | 2,815,157 | 13,361,426 |
Sector | Energy | Health |
52-Week High | $32.36 | $226.30 |
52-Week Low | $21.24 | $22.36 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $6.88B | $82.48B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Magnolia Oil & Gas (MGY) trades at $25.11, up 2.66% with neutral technical signals. The company demonstrates strong fundamentals with a P/E of 10.97, net income margin of 28.77%, and consistent earnings beats. Recent WildFire Energy acquisition positions MGY for production doubling and significant free cash flow growth, with 2027 FCF projected over $1 billion. Analyst consensus remains strongly bullish with 66.7% buy ratings and $33.78 price target.
MGY presents compelling value with attractive valuation multiples and robust profitability metrics. The WildFire acquisition accelerates growth but introduces integration execution risk. Current price offers 35% upside to consensus target, though oil price volatility and operational execution remain key watchpoints for investors.
Moderna (MRNA) trades at $216.25, up 1.17% with a bullish technical signal and recent Nasdaq-100 inclusion driving momentum. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with a net income margin of -142.58% and declining revenue from $18.9B in 2022 to $1.92B in 2025. The stock's 500% rally in 2026 has pushed valuations to elevated levels with a P/S of 38.5, creating divergence between technical strength and financial performance.
The outlook remains polarized with Nasdaq inclusion providing institutional support but valuation concerns capping upside. Investment opportunity lies in the cancer vaccine pipeline, while risks include sustained profitability challenges and competitive pressures. Analyst consensus at $115.70 suggests significant downside from current levels, with only 28% recommending buy ratings amid ongoing operational cash flow deficits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Magnolia Oil & Gas Corporation Class A Common Stock
Magnolia Oil & Gas Corporation is an independent oil and gas exploration and production company operating in the Eagle Ford Shale and Austin Chalk formations of South Texas.
Read more on MGY →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
